Oramed Pharmaceuticals Inc (ORMP) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Oramed Pharmaceuticals Inc stock (ORMP) is currently trading at $3.50. Oramed Pharmaceuticals Inc PE ratio is 3.55. Oramed Pharmaceuticals Inc PS ratio (Price-to-Sales) is 70.73. Analyst consensus price target for ORMP is $6.25. WallStSmart rates ORMP as Underperform.
- ORMP PE ratio analysis and historical PE chart
- ORMP PS ratio (Price-to-Sales) history and trend
- ORMP intrinsic value — DCF, Graham Number, EPV models
- ORMP stock price prediction 2025 2026 2027 2028 2029 2030
- ORMP fair value vs current price
- ORMP insider transactions and insider buying
- Is ORMP undervalued or overvalued?
- Oramed Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- ORMP Piotroski F-Score and Altman Z-Score
- ORMP analyst price target and Smart Rating
Oramed Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
ORMP Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Oramed Pharmaceuticals Inc (ORMP)
ORMP trades at a significant discount to its Graham intrinsic value of $46.80, offering a 93% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Oramed Pharmaceuticals Inc (ORMP) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, price/book, eps growth. Concerns around market cap and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Oramed Pharmaceuticals Inc (ORMP) Key Strengths (4)
Trading below book value, meaning the market prices it less than net assets
Earnings per share surging 40.90% year-over-year
Keeps $2193 of every $100 in revenue as net profit
Every $100 of equity generates $25 in profit
Supporting Valuation Data
Oramed Pharmaceuticals Inc (ORMP) Areas to Watch (5)
Losing money on operations
Revenue declining -100.00%, a shrinking business
Very expensive at 70.7x annual revenue
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Oramed Pharmaceuticals Inc (ORMP) Detailed Analysis Report
Overall Assessment
This company scores 49/100 in our Smart Analysis, earning a D+ grade. Out of 9 metrics analyzed, 4 register as strengths (avg 9.8/10) while 5 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, EPS Growth, Profit Margin. Valuation metrics including Price/Book (0.69) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 24.50%, Profit Margin at 2193.00%. Growth metrics are encouraging with EPS Growth at 40.90%.
The Bear Case
The primary concerns are Operating Margin, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (70.73) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Operating Margin at -651.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 24.50% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ORMP Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ORMP's Price-to-Sales ratio of 70.73x trades at a deep discount to its historical average of 583.23x (37th percentile). The current valuation is 99% below its historical high of 4771.88x set in Jan 2014, and 160% above its historical low of 27.24x in Oct 2023.
WallStSmart Analysis Synopsis
Data-driven financial summary for Oramed Pharmaceuticals Inc (ORMP) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Oramed Pharmaceuticals Inc faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 2M with 100% decline year-over-year. Profit margins are strong at 2193.0%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 24.5% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Spending 58% of revenue (1M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Oramed Pharmaceuticals Inc.
Bottom Line
Oramed Pharmaceuticals Inc faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(34 last 3 months)
| Insider | Type | Shares |
|---|---|---|
KIDRON, NADAV Director, President and CEO | Sell | -100,000 |
| Insider | Type | Shares |
|---|---|---|
KIDRON, MIRIAM Director, Chief Scientific Officer | Sell | -86,166 |
Data sourced from SEC Form 4 filings
Last updated: 10:07:04 AM
About Oramed Pharmaceuticals Inc(ORMP)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Oramed Pharmaceuticals Inc. is dedicated to the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for the administration of polypeptides. The company is headquartered in New York, New York.